For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

You are here


Found 59 results
Author Title Type [ Year(Desc)]
Filters: Author is Nathan, Carl F  [Clear All Filters]
Nathan C, Cars O.  2014.  Antibiotic resistance--problems, progress, and prospects.. N Engl J Med. 371(19):1761-3.
Botella H, Yang G, Ouerfelli O, Ehrt S, Nathan CF, Vaubourgeix J.  2017.  Distinct Spatiotemporal Dynamics of Peptidoglycan Synthesis between Mycobacterium smegmatis and Mycobacterium tuberculosis.. mBio. 8(5)
Nathan C.  2017.  Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Nathan C, Nussenzweig MC, Pulvirenti T.  2017.  JEM Advisory Editorial Board: Increasing diversity.. J Exp Med.
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..  2017.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
Gold B, Nathan C.  2017.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.. Microbiol Spectr. 5(1)